More tools:Markets·Screener·Research·Chat

AIM ImmunoTech Inc. (AIM) Financial Statements

AIM ImmunoTech Inc.
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SB9J29
XASE · usd
0.23▼ 0.00 (-0.30%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close0.23
Day's Range0.23 – 0.24
52-Week Range0.19 – 2.98
Volume5.7M
Avg Volume7.8M
Share Statistics
Shares Outstanding
Employees21
ExchangeXASE
Listed1995-11-02
Share count as of August 7, 2026
Loading Income Statement…
Key questions about AIM ImmunoTech Inc. (AIM)
What is AIM ImmunoTech Inc.'s Market Cap?
AIM ImmunoTech Inc.'s Market Cap is $7.0M, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s Enterprise Value?
AIM ImmunoTech Inc.'s Enterprise Value is $628.2K, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s Price / Sales?
AIM ImmunoTech Inc.'s Price / Sales is 73.4×, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s EV / Revenue?
AIM ImmunoTech Inc.'s EV / Revenue is 6.6×, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s EV / EBITDA?
AIM ImmunoTech Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s Revenue (TTM)?
AIM ImmunoTech Inc.'s Revenue (TTM) is $95.0K, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s Net Income (TTM)?
AIM ImmunoTech Inc.'s Net Income (TTM) is -$14.3M, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s EBITDA?
AIM ImmunoTech Inc.'s EBITDA is -$11.0M, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s Diluted EPS (TTM)?
AIM ImmunoTech Inc.'s Diluted EPS (TTM) is -0.47, based on as-reported figures from SEC (XBRL) filings.
What is AIM ImmunoTech Inc.'s EBITDA Margin?
AIM ImmunoTech Inc.'s EBITDA Margin is -11530.5%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Revenue
YoY growth+4.0%+37.5%-53.3%-25.7%
Costs and Expenses:
Cost of Revenue
Research and Development Expense
Selling, General and Administrative Expense
Total Costs and Expenses
% of revenue13611.5%10218.2%14157.1%9511.5%
Operating loss
% of revenue-13511.5%-10118.2%-14057.1%-9411.5%
Gain/Loss on Investments
Non-Operating Income (Expense)
Interest expense and other finance costs
Loss on change in fair value of warrant liability
Net Loss
% of revenue-14569.2%-13740.9%-19881.0%-12630.8%
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—